id: lack_authorized_therapies_to_mortality_alcohol_hepatitis
name: Lack of Authorized Therapies for Severe Alcohol-Associated Hepatitis â†’ Mortality
  from Alcohol-Associated Hepatitis
from_node:
  node_id: lack_authorized_therapies
  node_name: Lack of Authorized Therapies for Severe Alcohol-Associated Hepatitis
to_node:
  node_id: mortality_alcohol_hepatitis
  node_name: Mortality from Alcohol-Associated Hepatitis
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: No authorized pharmacological treatments exist for severe alcohol-associated
  hepatitis beyond corticosteroids'
- 'Step 2: Limited therapeutic options mean clinicians can only offer supportive care
  and transplantation'
- 'Step 3: Patients who fail corticosteroid therapy or are not transplant candidates
  have no effective alternatives'
- 'Step 4: High short-term mortality persists due to therapeutic gap in severe disease
  management'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Cyriac Abby Philips 2024. "A comprehensive review of diagnosis
    and management of alcohol-associated hepatitis.." *SAGE open medicine*. https://doi.org/10.1177/20503121241297000
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:05.386991'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: clinical_trial_access
  direction: weakens
  strength: moderate
  description: Enrollment in clinical trial programs can provide experimental bridge-to-transplant
    or salvage therapy options for rapidly deteriorating patients
- name: geographic_proximity_research_centers
  direction: weakens
  strength: moderate
  description: Proximity to academic medical centers conducting trials on healthy
    donor stool transplant or targeted bacteriophage therapy may improve outcomes
